581 results
P
I/C
l, o, w, -, l, e, v, e, l, , a, r, s, e, n, i, c, , (, A, s, ), , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r, d, r, i, n, k, i, n, g, , w, a, t, e, r, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, s, , l, o, w, e, r, , t, h, a, n, , t, h, e, , W, H, O, , p, r, o, v, i, s, i, o, n, a, l, , g, u, i, d, e, l, i, n, e, , v, a, l, u, e, , (, 1, 0, , µ, g, /, L, )
O
p, o, o, l, e, d, , a, s, s, o, c, i, a, t, i, o, n, , b, e, t, w, e, e, n, , t, h, e, , r, e, l, a, t, i, v, e, , r, i, s, k, , o, f, , e, a, c, h, , c, a, r, d, i, o, v, a, s, c, u, l, a, r, , d, i, s, e, a, s, e, , (, C, V, D, ), , e, n, d, p, o, i, n, t, , a, n, d, , l, o, w, -, l, e, v, e, l, , A, s, , c, o, n, c, e, n, t, r, a, t, i, o, n, , i, n, , d, r, i, n, k, i, n, g, , w, a, t, e, r
P
solid tumors, gastric cancer, pancreatic cancer, colorectal cancer
I/C
HLA-G expression, no HLA-G expression
O
worse survival
P
women with at least one implantation failure
I/C
G-CSF administration, no G-CSF administration
O
clinical pregnancy rate (CPR), implantation rate (IR), biochemical pregnancy rate (BPR), live birth rate (LBR)
P
adults
I/C
SES (e.g. income), EOL costs in last year(s) or month(s) of life
O
correlated, positively correlated, inversely correlated
P
GSNO
I/C
S-Nitrosoglutathione, Placebo
O
Infarct size, Neurological behavior scales, Embolic signals
P
CP, AP, PI, healthy peri-implant, healthy controls
I/C
TNF-α (G-308A) polymorphism, variant A of TNF-α (G-308A)
O
susceptibility to CP and AP, elevated risk of CP and AP, no association with PI risk
P
health professionals (HPs)
I/C
formal R/S-training, physicians, nurses
O
belief in influence of R/S on patients' health, prevalence of formal R/S-training
P
patients with head and neck cancer
I/C
surgical treatment, gastrostomy tube (G-tube) placement, pedicled flaps versus free flaps
O
postoperative G-tube placement
P
ICU patients
I/C
protein provision, <1.2 g/kg protein
O
60-day mortality, nitrogen balance, changes in muscle mass
P
metastatic or recurrent gastric cancer patients
I/C
capecitabine-based chemotherapy, S-1-based chemotherapy
O
objective response rate, 6-, 12-, and 18-month progression-free survival, 1-, 2-, and 3-year overall survival, adverse events (hand-foot syndrome, neutropenia)